Laboratory of Lymphocyte Signaling and Oncoproteome

Marco Herling, MD


Dr. Herling graduated from Martin-Luther-University (MLU) Halle-Wittenberg medical school in 1999. In his doctoral theses work on experimentally induced soft tissue sarcomas from 1994-1999 at the MLU Institute of Pathology, he studied pre-malignant mesenchymal changes and tumor host interactions on the basis of cellular glycoprotein-receptor patterns. With a stipend through the Biomedical Sciences Exchange Program, Dr. Herling worked as a medical student with mentors Drs. A.H. Sarris and L.J. Medeiros on the development of prognostic marker profiles in anaplastic large cell lymphoma and Hodgkin lymphoma between 1997-98 at the Department of Lymphoma and Myeloma at the M. D. Anderson Cancer Center (MDACC), Houston, Texas. In 2000, he entered his clinical training at the Department of Hematology/Oncology at the University of Freiburg chaired by Dr. R. Mertelsmann. He spent his postdoctoral fellowship from 2002-2006 at the MDACC’s Department of Hematopathology in the laboratory of Dr. D. Jones. There, he investigated transforming mechanisms in T-cell malignancies with focus on the role of the oncogene TCL1. Between 2002-05, Dr. Herling was enrolled in the NIH Physician Scientist Training Program headed by Dr. E. J. Freireich completing the curriculum with a proposal and clinical implementation of novel trial approaches in T-PLL. As an awardee of the MDACC Odyssey Fellowship, Dr. Herling extended his research to the signaling pathways relevant in the precursor transformation and tumor progression in CLL.

With a stipend by the DFG, he joined the team around Dr. M. Hallek at the Department of Medicine I at Cologne University in 2007, where he led a Max-Eder junior research group from 2008 -2015 around the description and targeting of kinase interactions induced by environmental survival signals in CLL. He also headed the departmental diagnostic immunophenotyping in 2006 – 2010.

As a specialist in Internal Medicine and Hematology and Oncology, he oversees the scientific and clinical program in mature T-cell leukemias, e.g. T-PLL including a second-opinion office or a nation-wide registry.

Since 2010 Dr. Herling holds a position as Adjunct Assistant Professor at the Department of Hematopathology at the MDACC.

Dr. Herling is a member of the American Society of Hematology, the American Society of Oncology, the American Association for Cancer Research, the German Society of Hematology and Oncology and other societies.

Scientific focus

  • The role and regulation of antigen receptor signaling in lymphatic oncogenesis
  • Specific interception in protein kinase interactions in oncogenesis
  • Environmental niches in mature B-cell and T-cell lymphomagenesis
  • Histogenetic, functional, and target-based classification of lymphatic tumors

Clinical focus

  • Optimized therapies for mature T-cell tumors
  • Diagnosis, prognostication and clinical management of mature lymphatic malignancies of T-cell and B-cell lineage
  • Novel approaches to clinical trial designs in translational malignant Hematology Evidence based supportive care



Alkylating deacetylase inhibitor tinostamustine in T-PLL

March 11, 2020

New letter evaluating the effects of EDO-S101/tinostamustine published in Leukemia.

Advances and Perspectives in the Treatment of T-PLL

Advances and Perspectives in the Treatment of T-PLL

February 25, 2020

New review on current and future strategies in treating T-PLL published in Current Hematologic Malignancy Reports

JAK/STAT-Activating Genomic Alterations Are a Hallmark of T-PLL

November 21, 2019

New meta-analysis on JAK/STAT genomic alterations in T-PLL published in Cancers.

We congratulate Dr. Sebastian Oberbeck on his PhD defence!

We congratulate Dr. Sebastian Oberbeck on his PhD defence!

October 30, 2019

On October 30th, Sebastian Oberbeck successfully defended his PhD. Congratulations!